Fibroblast growth factor 23 is associated with the presence of coronary artery disease and the number of stenotic vessels. (November 2015)
- Record Type:
- Journal Article
- Title:
- Fibroblast growth factor 23 is associated with the presence of coronary artery disease and the number of stenotic vessels. (November 2015)
- Main Title:
- Fibroblast growth factor 23 is associated with the presence of coronary artery disease and the number of stenotic vessels
- Authors:
- Hu, Xiang
Ma, Xiaojing
Pan, Xiaoping
Hao, Yaping
Luo, Yuqi
Lu, Zhigang
Bao, Yuqian
Jia, Weiping - Abstract:
- <abstract abstract-type="main" id="cep12467-abs-0001"> <title>Summary</title> <p>Fibroblast growth factor 23 (FGF23) has been reported to be involved in cardiovascular disease. The aim of this study was to investigate the association between FGF23 and the presence of coronary artery disease (CAD), as well as the number of stenotic vessels. A total of 254 eligible participants (167 men and 87 postmenopausal women) were enrolled in this study. Coronary angiography was used for diagnosis of CAD. Serum intact FGF23 levels were determined by a two‐sided sandwich enzyme‐linked immunosorbent assay. The median serum FGF23 levels of the entire study population were 39.9 (33.1–47.5) pg/mL. Serum FGF23 levels were higher in subjects with one‐vessel disease than those without CAD (<italic>P </italic>&lt;<italic> </italic>0.05), which further increased significantly in the subjects with multi‐vessel disease (<italic>P </italic>&lt;<italic> </italic>0.05). Serum FGF23 levels increased with cumulative number of stenotic vessels (<italic>P</italic> for trend &lt; 0.001). Multiple stepwise regression analysis revealed estimated glomerular filtration rate (standardized <italic>β </italic>= −0.298; <italic>P </italic>&lt;<italic> </italic>0.001) and body mass index (standardized <italic>β </italic>= 0.132; <italic>P </italic>=<italic> </italic>0.049) were independent factors correlated with FGF23. Multivariate logistic regression analysis showed that FGF23 was positively and independently<abstract abstract-type="main" id="cep12467-abs-0001"> <title>Summary</title> <p>Fibroblast growth factor 23 (FGF23) has been reported to be involved in cardiovascular disease. The aim of this study was to investigate the association between FGF23 and the presence of coronary artery disease (CAD), as well as the number of stenotic vessels. A total of 254 eligible participants (167 men and 87 postmenopausal women) were enrolled in this study. Coronary angiography was used for diagnosis of CAD. Serum intact FGF23 levels were determined by a two‐sided sandwich enzyme‐linked immunosorbent assay. The median serum FGF23 levels of the entire study population were 39.9 (33.1–47.5) pg/mL. Serum FGF23 levels were higher in subjects with one‐vessel disease than those without CAD (<italic>P </italic>&lt;<italic> </italic>0.05), which further increased significantly in the subjects with multi‐vessel disease (<italic>P </italic>&lt;<italic> </italic>0.05). Serum FGF23 levels increased with cumulative number of stenotic vessels (<italic>P</italic> for trend &lt; 0.001). Multiple stepwise regression analysis revealed estimated glomerular filtration rate (standardized <italic>β </italic>= −0.298; <italic>P </italic>&lt;<italic> </italic>0.001) and body mass index (standardized <italic>β </italic>= 0.132; <italic>P </italic>=<italic> </italic>0.049) were independent factors correlated with FGF23. Multivariate logistic regression analysis showed that FGF23 was positively and independently associated with the presence of CAD (odds ratio = 1.058, 95% confidence interval<italic> </italic>= 1.025–1.092; <italic>P </italic>=<italic> </italic>0.001). Additionally, FGF23 was also correlated with multi‐vessel disease significantly (odds ratio = 1.034, 95% confidence interval = 1.007–1.062; <italic>P </italic>=<italic> </italic>0.013). In conclusion, serum FGF23 levels exhibit positive and independent association with the presence of CAD and increase with the cumulative number of stenotic vessels.</p> </abstract> … (more)
- Is Part Of:
- Clinical and experimental pharmacology and physiology. Volume 42:Number 11(2015:Nov.)
- Journal:
- Clinical and experimental pharmacology and physiology
- Issue:
- Volume 42:Number 11(2015:Nov.)
- Issue Display:
- Volume 42, Issue 11 (2015)
- Year:
- 2015
- Volume:
- 42
- Issue:
- 11
- Issue Sort Value:
- 2015-0042-0011-0000
- Page Start:
- 1152
- Page End:
- 1157
- Publication Date:
- 2015-11
- Subjects:
- Clinical pharmacology -- Periodicals
Pharmacology, Experimental -- Periodicals
Physiology, Experimental -- Periodicals
Physiology, Pathological -- Periodicals
615.1 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=cep ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1440-1681.12467 ↗
- Languages:
- English
- ISSNs:
- 0305-1870
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.252000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3764.xml